Likelihood of Approval and Phase Transition Success Rate Model – Ipilimumab + Nivolumab in Malignant Fibrous Histiocytoma

Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Ipilimumab + Nivolumab in Malignant Fibrous Histiocytoma report and make more profitable business decisions.

This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.

Ipilimumab + Nivolumab in Malignant Fibrous Histiocytoma Drug Details:

Nivolumab and Ipilimumab (Opdivo and Yervoy) a drug regimen is a recombinant human IgG4 anti-PD-1 monoclonal antibody. It is formulated as solution concentrate for intravenous route of administration. Opdivo and Yervoy drug regimen is indicated to treat advanced metastatic melanoma and for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma, and unresectable malignant melanoma. Opdivo and Yervoy combination is indicated for treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. nivolumab (Opdivo) in combination with ipilimumab (Yervoy), as first-line treatment for patients with metastatic non-small cell lung cancer whose tumors express PD-L1(=1%), as determined by an FDA-approved test, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, and also nivolumab in combination with ipilimumab ( and 2 cycles of platinum-doublet chemotherapy as first-line treatment for patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. Opdivo in combination with Yervoy for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery. Opdivo in combination with Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) with tumor cell PD-L1 expression = 1%. Opdivo in combination with Yervoy is indicated for the first-line treatment of unresectable, advanced or recurrent esophageal cancer in adults. Opdivo in combination with Yervoy as a first-line treatment for adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC), for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR) colorectal cancer (CRC).The drug candidate is under development for the treatment of recurrent endometrial carcinoma, metastatic adenocarcinoma of the pancreas, metastatic or recurrent squamous-cell lung cancer (SqLC), glioblastoma multiforme, gliosarcoma, neuroendocrine carcinoma, intrahepatic cholangiocarcinoma, gallbladder carcinoma, uterine clear cell carcinoma, vulva squamous cell carcinoma and vaginal squamous cell carcinoma, advanced rectal adenocarcinoma, cutaneous squamous cell carcinoma, relapsed and refractory multiple myeloma, recurrent metastatic head and neck squamous cell cancer, recurrent or progressive high grade glioblastoma, cutaneous melanoma, epithelial ovarian cancer, fallopian tube cancer and peritoneal cancer second and third line therapy (intraperitoneal route), metastatic uveal melanoma, recurrent head and neck cancer squamous cell carcinoma, esophageal squamous cell carcinoma, gastric cancer or gastric-esophageal cancer, renal cell carcinoma, salivary gland cancer, melanoma, HER2 negative, triple negative breast cancer, squamous and non-squamous non-small cell lung cancer, small cell lung cancer, papillary renal cell carcinoma, NET of the pancreas, lung or gastrointestinal (GI) tract, Kaposi sarcoma, metastatic homologous-recombination deficient (HRD) castration-resistant prostate cancer (mCRPC), metastatic pancreatic cancer, metastatic colorectal cancer, biliary tract carcinoma, head and neck squamous cell cancer, metastatic uveal melanoma, metastatic urothelial cancer, bladder cancer, anal, vulvar, penile, colorectal, cervical, esophageal cancer, adenoid and non-adenoid cystic carcinoma, meningioma, dedifferentiated liposarcoma, undifferentiated pleomorphic sarcoma, metastatic merkel cell carcinoma, nasopharyngeal carcinoma, adenocarcinoma of the gastroesophageal junction, medullary and anaplastic thyroid cancer, adrenocortical carcinoma, metastatic castration resistant prostate cancer, diffuse intrinsic pontine glioma (DIPG), high grade glioma (HGG), medulloblastoma, muscle invasive bladder cancer, metastatic basal cell carcinoma, ependymoma, angiosarcoma (AS), alveolar soft part sarcoma (ASPS), clear cell sarcoma (CCSA), desmoplastic small round cell tumor (DSRCT), sclerosing epithelioid fibrosarcoma (SEF), perivascular epithelioid cell tumor (PEComa), intimal sarcoma (IS), extraskeletal myxoid chondrosarcoma (EMC), solitary fibrous tumor (SFT), epithelioid hemangioendothelioma (EHE), inflammatory myofibroblastic tumor (IMT), epithelioid sarcoma (ES), fibrosarcoma (FS), SMARCA-4 deficient sarcoma, malign peripheral nerve sheath tumors (MPNST), chordoma, virus positive/negative solid carcinoma and malignant pleural mesothelioma. It was also under development for the treatment of epithelial ovarian cancer, small cell lung cancer, recurrent glioblastoma, fallopian tube cancer, melanoma, hepatic tumor, Wilms” tumor, neuroblastoma, non-rhabdomyosarcoma, head and neck cancer and peritoneal cancer. it is administered through intraperitoneal route.

Report Coverage

The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.

The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.

Quick View – Ipilimumab + Nivolumab LOA Data
Report Segments	· Drug type · Intervention type
Drug Name	· Ipilimumab + Nivolumab
Administration Pathway	· Intraperitoneal| Intravenous
Therapeutic Areas	· Non Malignant Disorders| Oncology
Key Manufacturers	· Bristol-Myers Squibb Co
Drug Development Status	· Marketed

Reasons to Buy

• Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
• Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
• Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
• Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.

Scope

• Drug Details: Drug name, Drug type, Intervention type
• Administration Pathway
• Therapeutic Areas
• Key Manufacturers
• Drug Development Status

This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.